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The immune system is primarily involved in protection 
against pathogens and opportunistic organisms. Simi-
lar to a nation’s defence organization, the immune 
system involves different components. This diversity 
allows the immune system to defend against different 
types of attacks by microbes. The past century has 
witnessed tremendous progress in understanding the 
components and mechanisms involved in the immune 
response. This article attempts to highlight areas of 
active research in basic immunology in the coming 
years. 
THE mechanisms by which vertebrates have devised sur-
vival strategies to protect themselves from pathogens and 
opportunistic organisms constitute the subject of immu-
nology and the past century has witnessed tremendous 
strides in the growth and establishment of this field1,2. 
This transition from an ‘esoteric’ science of undefined 
factors and mechanisms to ‘mainstream’ science has been 
due to the development of defined reagents: monoclonal 
antibodies, cDNAs and the use of genetically modified 
mice harbouring targeted mutations in immune function-
related genes. Although it is hazardous to predict the  
future, an attempt is made here to list some of growing 
areas of immunology in the coming years (Box 1). The 
knowledge obtained in these basic immunological pursuits 
finds applications in several other areas of applied immu-
nology and disease pathogenesis; however, not all aspects 
have been addressed in this article due to limitations of 
space. 
The two main arms of the immune response are innate 
and adaptive (Figure 1). The innate arm is evolutionarily 
conserved, acts early and constitutes the first line of  
defence. The adaptive arm is evolutionarily recent and the 
immune response is relatively delayed (compared to the 
innate system), to generate a specific response towards a 
particular antigen. This specificity is conferred by antigen- 
specific receptors on B cells and T cells. The past few 
decades have witnessed tremendous progress in under- 
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Box 1. Broad areas of active research in 
basic immunology 
1. Studying the components and mechanisms 
involved in the innate immune response. 
Understanding the mechanisms by which the 
innate response modulates the adaptive 
immune response. 
2. Events leading to activation, proliferation, 
death and homeostasis in lymphocytes (T cells, 
B cells and NK cells). 
3. Mediators and mechanisms involved in the 
interaction of lymphoid and non-lymphoid cells 
under normal, pathogenic and aberrant (e.g. 
autoimmune, allergic, etc.) conditions. 
4. Characterization of cells and mechanisms 
involved in immunological memory. 
5. Genomics and the immune response: Genes 
involved in immune defects/modulation of 
immune responses and the role of genetic 
polymorphisms in the immune response, dis-
ease resistance and susceptibility. 
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standing the molecular basis of adaptive responses via the 
elucidation of the genes and structures of the B cell recep-
tor (BCR) and the T cell receptor (TCR) (Box 2). How-
ever, less is known of the innate arm of the immune 
system, which recognizes microbial components. For  
example, lipopolysaccharide (LPS), a component of 
Gram-negative bacteria, activates B cells and macro-
phages. Also, LPS is responsible for endotoxic shock, 
resulting in hypotension and multi-organ failure3. A better 
understanding of the m diators and the mechanisms  
involved in endotoxic shock is required as this informa-
tion may lead to the development of therapeutic strate-
gies3,4. We are beginning to understand the mechanisms 
by which components of bacterial cells induce immune 
response, especially the role of TOLL-family proteins5 
and additional proteins6. Surprisingly, bacterial DNA con-
taining non-methylated CpG dinucleotides stimulates  
immune cells7. On the other hand, vertebrate DNA con-
tains mainly methylated CpG that is non-stimulatory. The 
stimulatory capacity of bacterial DNA is extremely pot nt 
and certain groups are attempting to use the ‘adjuvant 
capacities’ of these sequences in DNA vaccines8. Furth r, 
work will reveal the nature of receptors involved in spe-
cific recognition f bacterial DNA9, the cell biology of its 
endocytosis and finally, the mechanisms by which  
unmethylated CpG DNA triggers immune effector func-
tions. Therefore, the mechanisms by which microbial cells 
induce the innate system, as well as the manner in which
they may modify the adaptive immune response will be an 
area of active investigation. 
 The adaptive immune response can be subdivided into 
two types–the humoral response that is mediated by the 
secretion of immunoglobulins by B cells and the cellular 
immune response that is mediated by T cells. Cytotoxic T 
cells are responsible for killing nfected cells, whereas T 
helper cells produce interleukins (IL), the ‘hormones’ of 
the immune system, and modulate B cell responses. 
Unlike B cells which recognize epitopes on native anti-
gen, T cells recognize peptides presented on major histo-
compatibility complex (MHC)-encoded proteins (Box 2). 
There are two broad classes of MHC molecules – classical 
and non-classical. MHC class I and class II proteins  
belong to the classical group, are highly polymorphic and 
play a dominant role in the T cell-mediated ad ptive  
immune response. Interestingly, natural killer (NK) cells, 
a sub group of cells belonging to the innate arm of the 
immune response, survey cells for the lack of expression of 
MHC class I. They are aided in this job by NK receptors10, 
which survey cells for MHC class I expression; cells 
which do not express MHC class I proteins are targeted
for lysis. There is a lot to be learnt on how NK receptors 
mediate this function – in most cases recognition of MHC 
molecules by NK receptors prevents lysis of target cells; 
however, in some cases NK receptors activate target cell 
lysis. The basis for the differential response by NK recep-
tors (inhibition or activation) will be an area of active 
study. Recent studies have revealed the importance of 
no -classical MHC molecules which are not very poly-
morphic11. There are several cell-surface molecules that 
belong to this category and their function may vary from 
tran porting IgG (neonatal Fc receptor), iron absorption 
(HFE or the haemochromatosis gene product) and the 
presentation of glycolipids (e.g. galactosyl ceramide pres-
entation by clusters of differentiation-1 (CD1) to a sub-
group of T cells). Although previous work has focused on 
the more important polym rphic MHC class I and class II 
molecules, future work on non-classical molecules will 
reveal their unique functions. 
 Much progress has been made in understanding the 
mechanisms by which peptides are generated and bind 
MHC molecules for presentation to T cells. It is well 
known that majority of peptides bound to MHC molecules 
are ge erated from cellular proteins. Indeed, in the  
absence of a peptide, cell-surface expression of MHC 
molecules is low. During infection, a small proportion  
of peptides derived from the pathogen bind to MHC 
molecules and are expressed on the cell surface of antigen 
presenting cells (APCs) (Box 2). On recognition of this 
peptide/MHC complex via TCRs, specific T cells get  
activated and proliferate (Figure 2). The components of 
the MHC class I and class II antigen-processing pathways 
are well studied and perhaps, additional components and 
mechanisms involved in crosstalk between these two 
pathways will be discovered in the future. Although it is 
possible to predict MHC-binding peptides from a given 
sequence, the factors that contribute to the generation of 
‘immunogenic’ peptides from a given protein are y t to be 
understood. In fact, the relative abundance of peptide 
produced12 or the best predicted MHC-binding peptide 
may not generate a good cytotoxic T lymphocyte (CTL) 
response13,14. There are several possible reasons for this 
discrepancy – lack of generation of these peptides in vivo 
due to the inability of enzymes to generate this peptide, 
short half- ife of the peptide, inability of the peptide to be 
transported into compartments for MHC binding, inability 
to bind the MHC allele expressed by the individual or 
lack of T cells specific for this peptide/MHC complex. 
Therefore, key progress needs to be made in understand-
ing the rules involved in the generation of peptides from 
proteins, the rules that govern the ability of peptides to be  Figure 1. Simplistic view of the immune system. 
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 Box 2. Brief explanation of immunological terms 
Adjuvant: A substance which enhances the  
immune response to an antigen. 
Antigen presenting cells (APCs): Dendritic cells, 
Langerhans cells, macrophages, B cells, etc.  
that digest cellular or pathogen-derived proteins 
and present peptide–MHC complexes to T cells. 
During an immune response, these cells express 
high levels of costimulatory ligands on the  
cell surface. High levels of MHC-peptide and 
costimulatory ligand expression are important for 
T cell activation. 
Antigenic peptide: Cellular or pathogen-encoded 
proteins are digested and peptides derived from 
these proteins are presented on MHC molecules. 
Specific TCRs recognize antigenic peptides/MHC 
complexes. Agonist peptides mimic antigenic 
peptides, whereas antagonist peptides are closely 
related by sequence to the antigenic peptide, but 
inhibit the activation of specific T cells. 
Antibody: Immunoglobulins that specifically bind 
to antigens and are produced in response to  
antigen; the specificity of antibodies to different 
antigens is due to the variable regions present in 
the molecule. 
Antigen: A molecule that elicits the production 
of antibodies and/or can be processed by APCs 
to elicit a T cell response. 
Apoptosis: Programmed cell death associated 
with morphologic changes, e.g. nuclear fragmen-
tation, membrane blebbing and release of apop-
totic bodies. 
Autoimmunity: Abnormal immune response against 
self-antigens resulting in disease, e.g. systemic 
lupus erythematosus, rheumatoid arthritis, etc. 
B cells: Lymphocytes that mature in the bone 
marrow in mammals or the bursa of Fabricius in 
birds and express membrane-bound antibody. 
On binding antigen, B cells differentiate into 
plasma cells that secrete antibody molecules. 
B-cell receptor (BCR): The B cell membrane-
bound immunoglobulin which recognizes antigen 
and is associated with two signal transducing 
molecules, Ig a/Ig b. 
Clusters of differentiation (CD): Refer to a par-
ticular cell surface molecule. Antibodies to differ-
ent CD molecules are used to denote specific cell 
populations; for example CD4 is usually present 
on T helper cells, whereas CD8 is present on  
T cytotoxic cells. 
Costimulation: Optimal activation of T cells and 
B cells requires signalling via two receptors –
antigen-specific receptor (TCR or BCR) and a 
costimulatory receptor (CD28 or CD19/CD21). 
 
Cytotoxic T cells (CTLs): T cells expressing CD8, 
on recognition of antigenic peptide/MHC complex, 
differentiate into CTLs which can kill APCs or target 
cells. 
Immunosuppression: Inhibition of immune res-
ponses; some cytokines, e.g. TGF b and IL-10 are 
known to be immunosuppressive. 
Major histocompatibility complex (MHC): MHC 
molecules are polygenic, polymorphic and inducible 
with interferon-g. They were first recognized in 
transplantation due to the induction of vigorous graft 
rejections. Genes encoding MHC molecules are 
located on human chromosome 6 (HLA) or mouse 
chromosome 17 (H-2). Predominantly, the two types 
of MHC molecules are class I or class II. MHC  
class I molecules present peptides generated in  
the cytosol to CD8+ cytotoxic T cells, whereas the 
MHC class II molecules present peptides degraded 
in lysosome-like compartments to CD4+ T helper  
cells. 
Monoclonal antibody: Produced by a single clone 
of B-lymphocytes and, hence, possesses the same 
antigenic specificity. 
Mucosal immune system: The mucous mem-
branes lining the digestive, respiratory and urogeni-
tal systems are protected by a group of organized 
lymphoid tissues collectively called the mucosal  
associated lymphoid tissue (MALT). 
Naive cells: Mature T and B cells that have not 
encountered antigen; also called unprimed and  
virgin cells. 
T cells: Lymphocytes that express a TCR; most T 
cells mature in the thymus. 
T helper cells: T cells with CD4 expression on the 
cell surface are called Th cells (Th cells). T helper 
cells are divided into two populations–Th1 and Th2 
subsets. Th1 subset produces cytokines that sup-
port inflammation and cell-mediated responses, 
whereas Th2 subset produces cytokines that help B 
cells to produce antibodies. 
T cell receptor (TCR): The molecule expressed on 
the surface of T cells that recognizes antigenic pep-
tide/MHC complex via variable regions. TCRs are 
associated with a group of proteins known as the 
CD3 complex, which is important for signal trans-
duction. 
Thymic selection: A stringent process by which 
few thymocytes are selected to enter the peripheral 
circulation as mature T cells. Those thymocytes that 
can recognize self-MHC molecules are selected 
(positive selection) and autoreactive thymocytes are 
eliminated (negative selection). 
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transported into MHC-binding compartments, the role of 
additional peptide-binding proteins, the role of flanking 
sequences in a MHC-binding peptide, etc. Also, progress 
needs to be made on the mechanisms by which some  
peptides act as agonists, partial agonists (for example  
cytotoxicity without cytokine production) and antagonists 
(a non-functional TCR–MHC interaction)15. 
 Naive T cells enter peripheral circulation after under-
going thymic education. These T cells recognize self-
MHC–peptide complexes, but much remains to be learnt 
about the mechanisms by which T cells transduce signals 
to initiate activation (Figure 2). The mechanisms by 
which T cells are activated, the maze of kinases and 
phosphatases and the reorganization of cell-surfa  pro-
teins into supramolecular activation cluster (SMOCs)16 
need to be refined further. Similarly, the events involved 
in B cell activation need to be understood. Enhanced 
knowledge of B and T cell activation may lead to novel 
drug targets that control immune responses. Lymphocytes 
require signalling via antigen-sp cific receptors (BCR or 
TCR) and a second costimulatory recepto  (CD19/CD21 
on B cells and CD28 on T cells). The role of costimula-
tion is to amplify the signals received via the BCR or the 
TCR to elicit an immune response17,18. This is usually true 
for immune responses to a model antigen (e.g. ovalbu-
min). However, the role of costimulatory receptors  
appears to be less important in responses to pathogens 
since they activate the innate immune system, resulting in 
an inflammatory response19. This results in high expres-
sion of ligands important for costimulatory receptors. 
CD28 on T cells is a major positive costimulatory recep-
tor, whereas CTLA4 is a negative costimulatory receptor. 
Activating T cells via the clonally variable TCR and 
CD28 is required for optimal proliferation, whereas tick-
ling T cells via CTLA4 down-regulates T cell responses. 
However, CTLA4 can positively costimulate T cell pro-
liferation under some conditions20,21. How does this  
happen? What is the role of other costimulatory receptors 
and interleukins (for example, IL-1, IL-6, IL-12, etc.) 
which can also costimulate T cells? What is the role of the 
different cell-surface molecules in T cell activation and 
cytokine production? For example, CD40–CD40L inter-
actions help up-regulate the CD28–B7 responses22. Much 
n eds to be learnt on the signalling p thways and contri-
butions of different cell-surface receptors in lymphocyte 
activation. 
 On activation, T cells produce high levels of inter-
leukins and there has been a tremendous amount of work 
on the identification and characterization of these factors; 
f r example, IL-2, IL-4, etc. play a critical role in the 
modulation of the immune response. The ratio of these 
different interleukins results in the dominance of T helper, 
Th1 or Th2 type of immune responses, which is important 
in determining immune responses to pathogens and influ-
encing the development of autoimmune diseases and  
allergic responses23. The reasons for the predominance of 
either Th1 or Th2 responses are complex and are in the 
process of being defined24. For example, the interaction 
between ICAM1 and LFA1, which are involved in cell 
adhesion, blocks IL-4 production resulting in down-
modulation of Th2 cytokines25,26. Future work will proba-
bly focus on the interplay of interleukins with other non-
lymphoid cells and there are evidences that suggest that 
cytokines produced by T cells affect epithelial cells.  
Although there are tremendous numbers of cells associ-
ated with the mucosal system, these lymphocytes are pre-
vented from activation under normal conditions due to the 
production of immunosuppressive factors (e.g. IL-10, 
TGF-b, prostaglandin E2)27. An appreciation of the inter-
play of non-lymphoid cells and lymphoid cells under 
normal, pathogenic and automimmune conditions will 
contribute to our understanding of the immune response. 
Similarly, an in vivo appreciation of the mechanisms by 
which cells of the immune system (T and B) communicate 
with each other will hopefully be better appreciated in the 
future28. Therefore, future research will reveal more about 
the roles and contributions of different cells and media-
tors in gen rating the immune response. 
 The probability of finding an antigen-specific T cell is 
extremely tiny, approximately one specific T cell out of a 
total of ten thousand T cells. However, during infections 
Figure 2. Life history of a T lymphocyte. Majority of T cells enter the 
peripheral circulation (spleen, lymph node, etc.) after being selected in 
the thymus. On recognizing antigenic peptide–self-MHC complexes on 
the surface of APCs (e.g. dendritic cells, macrophages, B cells) specific 
T cells are activated, produce the autocrine growth factor IL-2 and 
proliferate. As levels of IL-2 drop, activated T cells undergo apoptosis. 
However, a small pool of memory T cells remain to fight future battles. 
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these specific T cells expand greatly (~ 104–105 times)  
to constitute the bulk of the immune response29. It is  
dangerous to have such a large number of activated T 
cells because the large amounts of interleukins or other 
factors produced by these cells may cause damage to 
other cells of the body, resulting in immunopathology. As 
the antigen is cleared the vast majority of such activated T 
cells undergo apoptosis, although a few memory T cells 
remain to fight future battles (Figure 2). It is important to 
emphasize that the immune system has devised mecha-
nisms to down-modulate an acute immune reaction. How 
does this happen? What are the mechanisms involved in 
this response? What are mechanisms involved in B cell 
memory? How does the generation of memory B cells 
differ from that of memory T cells? These are some ques-
tions that need to be addressed in the future. 
 Lymphocyte death occurs in both thymic and peripheral 
tissues and this death ensures tolerance and maintenance 
of immune homeostasis30. Lymphocyte deletion may be 
triggered via signals through antigen receptors, which 
recruit death receptor–ligand interactions, e.g. CD95/Fas/ 
Apo-1 and tumour necrosis factor (TNF) recepto s into 
this process31. There is a vast amount of information 
available about the interaction of these receptors with 
cellular proteins and molecular events of death pathways. 
However, the r gulation of these events, i.e. the decision 
of the lymphocyte to trigger apoptotic death as opposed to 
proliferation or survival in response to antigen receptor 
cross-linking, is as yet unknown. The past five years have 
seen a tremendous surge in our knowledge of the molecu-
lar events that regulate apoptotic death of cells. Caspases, 
a family of cysteine proteases, have been identified as the 
key effectors of apoptotic death pathways32. There has 
also been the delineation of two major apoptotic death 
pathways involving these death proteases in lymphocytes 
and other cells. The first is triggered via the death recep-
tors listed above and the second involves the mitochon-
dria. The mitochondrion is a key checkpoint in the death 
pathway and molecules like cytochrome , apoptosis acti-
vating factor-1 (Apaf-1) and a novel flavo protein, apop-
tosis inducing factor (AIF) are some of the apoptogenic 
molecules associated with this organelle33. Interestingly, 
most of these molecules are located in the intermembrane 
space (IMS) of the mitochondrion and the coming years 
should reveal more insights into the movement of these 
molecules through the outer membrane of undamaged 
mitochondria in dying cells. Although the primary focus 
in the field of cell death has been on the role of caspases, 
molecules like MHC class I and MHC class II, CD2, CD4 
and CTL-triggered target cell death appear to be inde-
pendent of known caspases. Future research in this field 
should provide a clearer understanding of the physiologi-
cal significance of these death pathways and perhaps,  
allow a better manipulation of these events as well. In this 
context it is interesting to note that recent studies have 
opened up the intriguing and somewhat unexpected possi-
bility of caspase involvement in the process of T ll acti-
vation as well34,35. 
 A recent finding is that MHC class I and class II mole-
cules are important in not only selecting T cells in the 
thymus, but are also important in maintaining naive T 
cells in the periphery (Box 2). In fact, peripheral T cells 
transferred into hosts lacking lymphocytes result in proli-
feration of these newly transferred T cells in a self-MHC-
dependent manner, until a certain number of T cells is 
reached. However, uncontrolled proliferation is pre-
vented. How is this performed? What are the controlling 
factors (perhaps, cytokines or cell surface receptors)  
involved in this process? Thus, not only are self-MHC 
mol cules important for selecting T cells in the thymus, 
but they are also important for their maintnance in the 
periphery. Intermediate affinity interactions between the 
TCR and self-MHC molecules help T cells to be posi-
tively selected in the thymus and survive in the periphery. 
On the other hand, high affinity interactions lead to dele-
tion of these T cells in the thymus as they may be auto-
reactive (negative selection). However, high affinity 
interactions in the periphery lead to proliferation of T 
cells and the effector T cell response and memory29. This 
scenario is different for memory T cells which do not  
require elf-MHC molecules for survival29. How are these 
signals perceived differently with different outcomes? Are 
ther  any differences between the signals in CD4+ Th and 
CD8+ CTL cells? What is the nature of these signals and 
why and how are these signals perceived differently by  
T cells? What is the role of costimulation in this process 
(if any)? These are all questions that are actively being 
asked by T cell biologists and there is no doubt that this 
area will be the focus of active research in the years  
to come. 
 The molecular basis for the human ‘nude’ phenotype 
(immunodeficiency accompanied by baldness) was rcently 
determined. This disease is caused due to a nonsense  
mutation in the winged-h lix-nude transcription factor, 
which is expressed in skin and thymic epithelial cells36. 
Genetic mapping has identified several loci known to be 
important in immune function (e.g. http://www.jax.org); 
however, the precise location of the genes responsible for 
a variety of immune defects has not been identified. The 
information derived from the sequencing of the mouse 
and human genomes will be used by immunologists to 
identify candidate genes involved in immune-related func-
tions, determine the molecular basis of immune defects 
and the role of polymorphisms. For example, humans w o 
do not express IFN-g-receptor are extremely susceptible 
to infection by bacteria which live in intracellular com-
partments within a host cell, e.g. mycobacteria37.  
Recently, the complete sequence and order of genes in the 
HLA complex was published38. Interestingly, only 40% of 
expressed genes in the HLA region (the most gene-dense 
r gion in humans) code for immune functions. As MHC 
genes are extremely polymorphic and there are numerous 
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associations between various genes in the HLA complex 
to disease phenotype, genome sequence information will 
make it easier to map, type, functionally analyse and accu-
rately predict patients who may be susceptible to a par-
ticular disease. Also, the gene array technique may reveal 
key molecules that are modulated by the immun  res-
ponse, revising our understanding of immune activation. 
For example it was thought that naive T cells are dormant; 
however new information using the array technique shows 
that naive T cells express large numbers of genes, but the 
messages of only a few genes increased with T cell activa-
tion39. In other words, immunologists will reap the bene-
fits of the tremendous information explosion once the 
complete mouse and human genomes are available. 
 Viruses have evolved a variety of mechanisms to down-
modulate immune responses, including MHC class I and 
class II down-regulation and cytokine modulation40. 
Studying the mechanisms by which viruses subvert the 
immune response may lead to the identification o  some 
potential drug targets. Another promising area of research 
is the study of mechanisms by which human patients resist 
viral infections. For example, work on human survivors of 
HIV41 and Ebola42 has revealed that patients who secrete 
higher levels of cytokines stand a better chance of survival 
compared to patients who mount a slow and low cytokine 
response. This is a fine example on how knowledge of 
basic immunology helps us to design experiments to  
understand how some humans become resistant to diffe-
rent viruses in a ‘real life’ situation. Understanding these 
host defence factors in a variety of diseases may help us 
devise mechanisms to fight different kinds of disea es. 
 The past few decades have witnessed an enormous  
appreciation of the basic components that constitute the 
immune system. The coming years will elucidate the iden-
tification and roles of cell surface receptors, interleukins 
and transcription factors. The next decades will probably 
focus on the signalling components, understanding the 
system as a whole (crosstalk between different compo-
nents of the immune system as well as immune/non-
immune cell interaction) and immunogenetics will gain 
importance. Understanding the molecular details involved 
in an immune response will help to modulate the immune 
response, which may help in designing more effective 
therapeutic strategies. There is no doubt that rapid pro-
gress will be made in understanding basic mechanisms in 
immunology in this century; hopefully, some of these con-
tributions will emanate from laboratories in India. 
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